Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6546062 | 1.00 | MME (0.42) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL814779 | 1.00 | MME (0.42) | MMERAB9AACECPA1ACE2 | |
| Hydrochloric Acid SCHEMBL13726045 | 0.97 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL3508862 | 0.81 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL596422 | 0.81 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL596424 | 0.81 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL14944823 | 0.81 | KDM5B (0.36) | MMERAB9AACETP53KDM5B | |
| SCHEMBL20981925 | 0.79 | TGFBR1 (0.50) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL15154265 | 0.79 | MME (0.39) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL28470159 | 0.77 | CA14 (0.46) | SMN1; SMN2ALDH1A1MAPTMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326874-A1 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | The Regents of University of California (US) | 2024-02-28 | — | — | EP | claimed |
| CN-117561336-A | In vivo lentivirus gene therapy for the treatment of primary hyperoxaluria type 1 | 能源环境和技术研究中心OAMP | 2024-02-13 | — | — | CN | claimed |
| US-20230183706-A1 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | BANK OF AMERICA, N.A. | 2023-06-15 | — | — | US | claimed |
| EP-4121534-A1 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | Alnylam Pharmaceuticals, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| WO-2022225915-A1 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-27 | — | — | WO | claimed |
| CN-114929282-A | Asialoglycoprotein receptor mediated delivery of therapeutically active conjugates | 阿克丘勒斯治疗公司 | 2022-08-19 | — | — | CN | claimed |
| CN-110483319-B | Preparation method of N-alkoxy oxalyl alanine ester | 山东新和成精化科技有限公司 | 2022-08-05 | — | — | CN | claimed |
| WO-2021188611-A1 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | WO | claimed |
| CN-109293525-B | Micro-channel reactor and method for preparing N-alkoxy oxalyl alanine ester by using same | 山东新和成精化科技有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-110483319-A | A kind of preparation method of N- alkyloxy oxalyl alanine ester | SHANDONG XINHECHENG FINE CHEMICAL TECH CO LTD | 2019-11-22 | — | — | CN | claimed |
| US-20070048728-A1 | Hydroxylases and modulators thereof | ISIS INNOVATION LIMITED (GB) | 2007-03-01 | — | — | US | claimed |
| WO-2007009044-A2 | INHIBITORS OF EGLN3 ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DANA FARBER CANCER INSTITUTE, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2006092650-A2 | A COMPOSITION FOR CREATING AN ARTIFICIAL BONE -MARROW LIKE ENVIRONMENT AND USE THEREOF | NATIONAL CENTRE FOR CELL SCIENCES (IN) | 2006-09-08 | — | — | WO | claimed |
| JP-2006504415-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1554394-A2 | ASPARAGINYL HYDROXYLASES AND MODULATORS THEREOF | ISIS INNOVATION LIMITED (GB) | 2005-07-20 | — | — | EP | claimed |
| EP-1451341-A4 | EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE | DANA FARBER CANCER INST INC (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040248139-A1 | Eit-6, a polypeptide encoded by an estrogen regulated gene | DANA-FARBER CANCER INSTITUTE, INC. | 2004-12-09 | — | — | US | claimed |
| EP-1451341-A2 | EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2004035812-A2 | ASPARAGINYL HYDROXYLASES AND MODULATORS THEREOF | ISIS INNOVATION LIMITED (GB) | 2004-04-29 | — | — | WO | claimed |
| WO-2003042363-A2 | EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2003-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183706-A1 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | AGXT, HAO1, HAAO | MME 1287/4885RAB9A 4172/4885ACE 175/4885 |
| US-20070048728-A1 | Hydroxylases and modulators thereof | EGLN3, HIF1AN, EGLN2 | MME 1106/4885RAB9A 4364/4885ACE 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.